Nardil (Oral)

Quick links to important sections

Nardil (Oral)

Method of action: Antidepressant

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nardil (Oral)

What is Nardil (Oral)? Quick Facts

Property Description
Active ingredient Phenelzine sulfate
Form Oral, film-coated tablet
Pharmacological class Monoamine Oxidase Inhibitor (MAOI)
Common use Treatment of specific depressive states
Origin Synthetic organic compound

What Type of Medicine is Nardil (Phenelzine)?

Nardil is a potent, prescription-only medication whose active component is phenelzine sulfate, a synthetic substance classified as an antidepressant and a Monoamine Oxidase Inhibitor (MAOI). This classification places Nardil within one of the earliest groups of drugs used to treat depressive disorders. Phenelzine sulfate is a hydrazine derivative, chemically distinguishing it from newer antidepressant classes like SSRIs or tricyclics. This chemical structure gives the medication its strong, long-lasting ability to inhibit specific enzymes in the brain. Nardil is often utilized only after trials with other common antidepressants have been unsuccessful, underscoring its reserve status within clinical practice.

Composition and General Therapeutic Purpose

Nardil is formulated as a single-active-ingredient product and is supplied in the form of a film-coated tablet designed for oral administration. The primary therapeutic goal of the medication is to address specific types of depression. Clinical reviews have noted its effectiveness in managing depressive states characterized as atypical or neurotic, particularly in challenging cases of treatment-resistant depression when patients have not found sufficient relief from other agents. The drug is designated for depression in patients who have not responded to other commonly used antidepressants. Its clinical use is often focused on individuals whose symptoms include prominent anxiety, phobic features, or mood reactivity.

Key Mechanism Principle (Identity-Level Explanation)

The fundamental function of Nardil is based on its mechanism as a non-selective, irreversible MAOI. This means the drug works by permanently binding to and blocking the Monoamine Oxidase (MAO) enzymes. By inhibiting the MAO enzymes, Nardil prevents the enzymatic breakdown of crucial monoamine neurotransmitters in the brain, such as Serotonin, Norepinephrine, and Dopamine. Pharmacological studies confirm this action leads to an increased concentration of these mood-regulating chemicals available to nerve cells, which forms the basis of the drug's efficacy for stabilizing mood.

Regulatory References

  1. [FDA Approved Labeling]
  2. FDA labeling

What side effects are possible with Nardil (Oral)?

Possible Side Effects and Safety Information

The safety profile of Nardil (phenelzine) is formally documented in government regulatory materials, including official prescribing information. This information details the documented adverse reactions, their frequency, and mandatory safety requirements.


Officially Documented Adverse Reactions

Side effects are categorized based on their frequency in regulatory documentation:

Classification Examples of Adverse Reactions (by Regulatory Listing)
Common Drowsiness, Dizziness, Orthostatic Hypotension (low blood pressure upon standing), Insomnia, Weight gain, Constipation, Sexual dysfunction.
Uncommon/Rare Seizures, Peripheral neuropathy, Arrhythmia, Purpura, Reversible Jaundice.
Very Rare Fatal progressive necrotising hepatocellular damage, Neuroleptic Malignant Syndrome (NMS), Respiratory depression.

Adverse effects are also grouped by the body system affected, including the Nervous System, Gastrointestinal, Vascular, and Hepatobiliary systems.


Serious Safety Considerations

The most serious reaction documented in regulatory labels is the Hypertensive Crisis, a potentially fatal event requiring adherence to a strict tyramine- and dopamine-restricted diet. Other serious reactions include forms of Hepatotoxicity (liver damage) and the risk of Suicidality (suicidal thoughts and actions), particularly during the initial months of treatment or following dose changes. Serotonin Syndrome is also a documented risk when Nardil is combined with specific other medications.


Regulatory Restrictions and Patterns

Nardil is contraindicated (should not be used) in patients with conditions such as severe renal impairment, a history of liver disease, or pheochromocytoma. A severe withdrawal syndrome may occur following abrupt discontinuation. Furthermore, patients should generally not undergo elective surgery requiring general or spinal anesthesia while taking this medication, as stated in the regulatory labels.

Overdose and Emergency Response

Overdosage with Nardil (phenelzine sulfate) is associated with severe, potentially life-threatening systemic and cardiovascular manifestations. A crucial feature documented in regulatory labeling is the delayed onset of symptoms, which may not appear immediately, with reports indicating a delay of up to 12 to 48 hours following ingestion.

Documented clinical manifestations of overdosage may involve CNS symptoms such as drowsiness, agitation, hallucinations, stiffly arched back (opisthotonos), tremor, and excitation. Cardiovascular signs can include an irregular pulse, palpitation, constricting chest pain, and severe fluctuations in blood pressure.

The most serious outcome officially documented is a Hypertensive Crisis, a severe escalation that carries the risk of circulatory collapse and intracranial bleeding. Other life-threatening states include convulsive seizures, hyperpyrexia (severe high fever), shock-like coma, and death.

Regulatory guidance mandates that immediate medical attention must be sought for any suspected overdose, regardless of whether symptoms are present. Emergency services should be contacted if the individual has collapsed, had a seizure, or cannot be awakened. Due to the high risk and delayed presentation, hospital monitoring and frequent observation of blood pressure are required. Treatment is generally symptomatic and supportive, and specific interventions are required for the Hypertensive Crisis, such as the mandated administration of phentolamine to lower blood pressure.

Therapeutic Uses of Nardil (Oral)

Nardil (Phenelzine) is commonly used to help manage symptoms in patients whose condition has been unresponsive to initial treatments. The medication is generally applied in settings where patients experience complex, symptom-driven clinical presentations and is considered relevant when treatment with more common agents has failed.


Therapeutic Focus

This medication is relevant across therapeutic domains involving persistent symptoms of major depressive disorder, atypical features, and specific anxiety disorders. Its use often involves conditions characterized by periods of heightened symptoms, specifically including treatment-resistant depression, social anxiety disorder, and panic disorder.

The medication is commonly used across conditions presenting with acute episodes characterized by atypical features. This symptom cluster includes symptoms related to heightened physiological activity such as mood reactivity, hypersomnia, hyperphagia, and leaden paralysis. Addressing these characteristic symptoms supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability.

The therapeutic scope is relevant for addressing symptoms that interfere with daily functioning linked to certain anxiety disorders, including marked interpersonal sensitivity and recurrent panic attacks. The relief provided helps patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.


Quick Fact: Relief for Atypical Symptoms Feature Benefit
Symptom Cluster Leaden paralysis, hypersomnia, hyperphagia
Clinical Context Refractory depression with reactive mood
Patient Benefit May assist with functional stability

Eligibility and Restrictions for Use

Eligibility Map: Who can and Cannot Use Nardil (Phenelzine)

The use of Nardil is strictly governed by regulatory labeling, limiting its prescription primarily to adult patients whose depressive illness has not responded to other commonly used antidepressants. Eligibility is defined by a set of absolute exclusions and specific restrictions based on a patient's health status and age.


Contraindicated Populations and Conditions

Nardil is formally contraindicated in several patient groups, meaning they must not use the medicine. These exclusions are primarily tied to major organ function and pre-existing conditions:

  • Patients with a history of liver disease or abnormal liver function tests.
  • Patients with severe renal impairment or renal disease.
  • Patients with congestive heart failure or cerebrovascular disease.
  • Patients with pheochromocytoma or known hypersensitivity to the drug.

Age and Physiological Status

Population Regulatory Status
Pediatric Patients Use is not approved as safety and efficacy have not been established.
Pregnant/Lactating Safe use has not been established.
Older Adults Use requires caution due to increased likelihood of age-related organ issues.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Nardil (phenelzine sulfate) carries extensive official restrictions on co-administration with other substances due to the risk of serious pharmacodynamic effects, primarily Hypertensive Crises and Serotonin Syndrome.

Contraindicated Combinations

Co-administration is formally prohibited with other Monoamine Oxidase Inhibitors (MAOIs), Sympathomimetic Drugs, Serotonergic Agents (e.g., SSRIs), certain Antidepressants (e.g., TCAs, Bupropion, Buspirone), and specific Opioids (e.g., Meperidine). Other prohibited substances include Dextromethorphan, Guanethidine, Cocaine, and local anesthetics containing sympathomimetic vasoconstrictors.

Timing and Separation Rules

Mandatory washout periods are required when switching therapies. At least 14 days should elapse between the discontinuation of Nardil and the initiation of most other restricted antidepressants or agents, or vice-versa. An exception is fluoxetine, which requires a minimum of five weeks between its discontinuation and the initiation of Nardil. The medicine must be discontinued at least 10 days prior to any elective surgery requiring general anesthesia.

Food and Substance Restrictions

Strict dietary and substance restrictions are mandated. The ingestion of Tyramine-Rich Foods (e.g., aged cheeses, wine, fermented meats, fava bean pods) and related compounds (e.g., L-Tryptophan) is prohibited during therapy and for at least two weeks after stopping treatment due to the risk of a Hypertensive Crisis. Alcohol and other CNS depressants are also restricted.

Pharmacokinetic and Pharmacodynamic Notes

Interactions involve the potentiation of monoamine effects. Furthermore, the official label notes that phenelzine prolongs the effect of Suxamethonium by reducing plasma cholinesterase concentrations and may cause opioid accumulation via MAOI inhibition of Cytochrome P450 enzymes. Caution is advised with Antihypertensive Drugs due to the risk of exaggerated hypotensive effects.

Mechanism of Action

Monoamine Oxidase Inhibition and Neurotransmitter Modulation

Nardil (phenelzine) is a monoamine oxidase inhibitor (MAOI) that works by irreversibly inactivating both MAO-A and MAO-B enzymes.

Irreversible Covalent Binding

The primary mechanism involves the non-selective formation of a covalent bond with the MAO enzymes, leading to their complete and sustained inactivation. This binding prevents the enzymes from performing their typical catabolic function of degrading monoamine neurotransmitters.

Synaptic Consequence

This enzyme inactivation results in an accumulation of monoamine neurotransmitters, specifically dopamine, norepinephrine, and serotonin, within the presynaptic terminal and the synaptic cleft. This elevated neurotransmitter availability in the central nervous system is the core pharmacodynamic action of phenelzine.

Dosage and Administration Information

How to Use Nardil (Phenelzine Sulfate)

Nardil is administered via the oral route as a film-coated tablet and its usage is characterized by a specific, phased approach to dosing and adjustment. The dosage schedule requires strict adherence to prescribed patterns for initiation, maintenance, and eventual discontinuation.


Standard Administration Schedule

Administration Detail General Parameters
Route of Administration Oral
Dosage Form Film-coated tablet (15 mg strength)
Intake Condition May be taken with or without food

Dosing and Course Structure

The use of phenelzine involves distinct periods of dosage adjustment. Treatment typically begins with a dose of 15 mg three times a day (45 mg daily). This is often increased to 60 mg per day, and may be raised up to a maximum recommended daily dose of 90 mg to achieve a sufficient clinical response. Many patients may not show a response until treatment has been continued at this higher level for at least four weeks.

Once the maximum benefit is realized, the dose is gradually reduced over several weeks to a lower maintenance range, usually between 15 mg and 45 mg per day. The goal is to maintain the therapeutic effect using the minimal effective amount of medication.

Procedural Administration Rules

Proper use dictates that the medication should not be stopped abruptly. Upon discontinuation of Nardil, the dose must be reduced slowly over a period of at least two weeks to minimize potential discontinuation symptoms. For older adults, therapy is typically initiated at the lower end of the adult dosing range due to age-related physiological changes.

Recent Clinical Evidence

Research evidence / Overview of studies for Nardil (Oral)

Evidence for Use in Atypical Major Depressive Disorder

Nardil was studied for patients whose depressive condition is characterized by a specific pattern of symptoms, often referred to as atypical major depressive disorder. Studies for this particular patient group have involved randomized controlled trials (RCTs), where the study design compared the medicine against both inactive placebos and older classes of antidepressants. These trials involved adult outpatients, and research examined changes in symptom severity over defined, short time intervals.

Studies monitored outcomes related to symptoms such as hypersomnia (excessive sleeping), hyperphagia (increased eating), and leaden paralysis (a feeling of heavy limbs). Studies report outcomes related to symptom measurement and overall clinical status.

Evidence for Social Anxiety Disorder and Panic Disorder

Nardil was studied for Social Anxiety Disorder (Social Phobia) and Panic Disorder. Research was evaluated in individuals with these conditions.

For social anxiety, studies explored the medication in controlled clinical trials, monitoring changes in anxiety symptoms using specific scales. Studies also included comparisons of the medication alone against other forms of management, such as psychotherapy. Findings describe patterns observed in the studies regarding how symptoms evolved in the observed populations during short-term treatment phases.

Similarly, research was evaluated in people experiencing Panic Disorder. Trials monitored the frequency and severity of episodic changes (panic attacks) and explored outcomes related to physical discomfort. Research describes that the study focus was observed in studies more consistently for the acute panic attacks themselves, and limited information is available for the associated avoidant behaviors (like agoraphobia).

What is Still Uncertain About the Research Base

The overall evidence landscape for Nardil contains several limitations that should be noted. A major limitation is the modest sample sizes and the reliance on historical trials, which means the evidence quality varies across studies. Comparative evidence is lacking, particularly against other commonly studied antidepressant agents. Furthermore, long-term effects are not fully established, and the evidence contributes to understanding short-term symptom patterns primarily. Data for certain groups, such as those with significant comorbidities or very young patients, remain insufficient.

Key Studies & References

  1. Phenelzine – treatment-resistant depression – EML (WHO Expert Review)

Frequently Asked Questions (FAQ)

Common questions about Nardil (Oral) (FAQ)


Q: How is Nardil different from SSRI or SNRI antidepressants?

A: Nardil belongs to a pharmacological class called Monoamine Oxidase Inhibitors (MAOIs), which are chemically distinct from newer drugs like SSRIs and SNRIs. Its unique mechanism involves the irreversible inactivation of MAO enzymes. Official guidance notes that Nardil is generally reserved for patients whose condition has not responded sufficiently to other commonly used antidepressant classes.


Q: What are the signs of a tyramine reaction while on Nardil?

A: A severe reaction known as a Hypertensive Crisis may occur if dietary restrictions are not followed. Regulatory documents describe the signs of this crisis as a sudden, very severe headache, neck pain or stiffness, and excessive sweating. Other reported symptoms include nausea, vomiting, fast heartbeats, and light sensitivity.


Q: Can Nardil affect blood pressure levels?

A: Yes, official labels describe that Nardil can influence blood pressure in both directions. Orthostatic Hypotension, a drop in blood pressure when standing up, is listed as a common adverse reaction. Conversely, the medication is associated with the serious risk of a Hypertensive Crisis, which is a potentially dangerous, sharp increase in blood pressure.


Q: Does Nardil interact with over-the-counter cold and flu medications?

A: The use of Nardil is contraindicated, or prohibited, with many common cold and flu medication ingredients. Specifically, this includes Sympathomimetic Drugs (like some decongestants) and the cough suppressant Dextromethorphan. These combinations are restricted according to regulatory guidance due to the potential risk of serious adverse effects.


Q: Does Nardil interact with dental anesthetics?

A: Regulatory documents indicate that local anesthetics containing sympathomimetic vasoconstrictors are formally contraindicated for use in patients taking Nardil. This warning is based on the risk of drug interactions.


Q: Are there any official reports of Nardil's effect on sexual health?

A: Yes, sexual dysfunction is listed in the official labeling as a common adverse reaction. Specific effects reported include decreased libido, abnormal ejaculation, and difficulty reaching orgasm or impotence.


Q: Are there any specific lab tests required before starting Nardil?

A: Official information states that Nardil is prohibited for use in patients with a history of liver disease or documented abnormal liver function tests. This indicates that information about a patient's liver function status is required before initiation of therapy can be considered.


Q: What happens if I forget to take a dose of Nardil?

A: Regulatory-derived patient information generally advises taking a missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the information generally describes skipping the missed dose and continuing with the regular schedule. Taking a double dose is described as prohibited.


Q: Are there any specific supplements or vitamins that interact with Nardil?

A: The official labeling prohibits the use of supplements containing compounds such as L-Tryptophan and L-Tyrosine. Combining Nardil with herbal products that affect serotonin levels is also restricted. There are no general contraindications for common vitamins in the official labeling.


Q: Can Nardil cause changes in vision or eye health?

A: Official product information indicates Nardil may cause effects such as mydriasis, which is the dilation of the pupil. This effect could potentially trigger an angle-closure attack in individuals susceptible to this eye condition. Blurred or decreased vision has also been reported as an adverse effect.


Q: Are there any common interactions between Nardil and herbal products?

A: Official regulatory information advises against combining Nardil with herbal products that are known to affect serotonin levels. This caution is due to the potential for an increased risk of developing Serotonin Syndrome, a serious condition.


Q: What information is available regarding Nardil use during pregnancy?

A: Regulatory documents state that the safety of Nardil use during pregnancy has not been established. Official information indicates that use is considered only when the potential benefit to the patient is judged to outweigh the potential risk to the fetus. Exposure late in the third trimester has been associated with reports of drug withdrawal and respiratory distress in neonates.


Q: Is it normal to feel certain new physical symptoms when first starting Nardil?

A: The regulatory label documents a list of commonly reported adverse reactions that may be experienced. These include symptoms like drowsiness, dizziness, insomnia, and dry mouth. Such symptoms are generally reported most frequently when first starting the medication or when a dose adjustment is made.


Q: Does Nardil have potential interactions with appetite suppressants?

A: Regulatory documents prohibit the use of Nardil with certain classes of drugs, including Sympathomimetic Drugs. This class of agents includes certain prescription medications that are used as appetite suppressants.


Q: Is Nardil associated with any specific effects on memory or concentration?

A: Official warnings state that the drug may impair judgment, thinking, or motor skills. This impairment could potentially affect a patient’s concentration. Dizziness and drowsiness are also listed as common adverse reactions that could impact these abilities.


Q: How does the structure of the Nardil molecule relate to its function?

A: Nardil's chemical structure is described as a hydrazine derivative. This structure allows the drug to function as a non-selective, irreversible MAOI, meaning it permanently binds to and blocks the MAO enzymes. This action is linked to the core therapeutic function of increasing the availability of monoamine neurotransmitters in the brain.


Q: Is Nardil covered by specific official patient information guides?

A: Yes, the regulatory requirements for the medication mandate the inclusion of specific patient-focused documents. These sections, often titled Patient Counseling Information or a Medication Guide, detail safety, administration, and warning information in language designed for patients.


Q: What happens to the body if the tyramine diet is not followed?

A: Official warnings state that failure to strictly adhere to the tyramine-restricted diet can lead to a potentially life-threatening event called a Hypertensive Crisis. This crisis is characterized by an extreme, rapid increase in blood pressure.


Q: Are there any official warnings about combining Nardil with herbal remedies for mood?

A: Official warnings prohibit combining Nardil with any substances, including herbal remedies that increase serotonin levels, such as St. John's Wort. This prohibition is due to the potential for a life-threatening reaction known as Serotonin Syndrome.


Q: How is Nardil's effect described on anxiety symptoms?

A: Studies and official information indicate that Nardil has been examined for use in conditions that feature anxiety, including Social Anxiety Disorder and Atypical Major Depressive Disorder. Research reports outcomes related to changes in specific anxiety symptoms as measured by clinical scales in the observed populations.


Q: Is Nardil described as having a risk of dependence or withdrawal?

A: Official documents describe the risk of a severe withdrawal syndrome following the abrupt or rapid discontinuation of the drug. This is described as a physiological effect, with reported symptoms including vivid nightmares, agitation, and psychosis.


Q: Is Nardil suitable for use in elderly patients?

A: Regulatory information indicates that use in the elderly population requires caution. This is due to the increased likelihood of age-related issues affecting organ function and the potential for the blood pressure-lowering effect to be more pronounced. Official guidance describes initiating therapy at the lower end of the adult dosing range for this population.

How should Nardil (Oral) be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal rules for Nardil (phenelzine sulfate) are strictly defined in regulatory documents to ensure the stability of the oral tablets.

Requirement Official Regulatory Statement
Temperature & Environment Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), or as specifically directed by local labeling (some regions require refrigeration).
Container & Protection Tablets must be dispensed in a tight, light-resistant container. The medicine must be protected from moisture and excess heat, with an explicit warning not to store in the bathroom.
Child Safety Keep this and all medicines out of the sight and reach of children.
Disposal Do not flush unused or expired medication down the toilet or pour it into a drain. Disposal should be carried out through an authorized medicine take-back program or according to local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nardil (Oral) found in:

A-Z Index: